



Alberto Orta Ruiz BSc. MD. PhD

Date of birth: 03/04/1983

Nationality: Spanish

CONTACT

5 Benito Gutierrez, 1º D
28008 Madrid, Spain

info@albertoortaruiz.com

(+34) 626944786

www.albertoortaruiz.com

WORK EXPERIENCE

01/08/2022 – CURRENT – Madrid, Spain

Consultant Physician in Medical Oncology

MD Anderson Cancer Center Madrid

Acute medicine & emergencies department

<https://mdanderson.es/>

05/2022 – CURRENT – Pamplona, Spain

Medical Director

Hyssogenix

Genetics based analysis as a predictive and prognostic biomarker of otological diseases.

<https://www.hyssogenix.com/>

05/2022 – 07/2022 – Madrid, Spain

Visiting Resident Physician in Medical Oncology

SERMAS - San Carlos Clinical University Hospital

05/2017 – 07/2022 – Madrid, Spain

Resident Physician in Medical Oncology

Fundación Jiménez Díaz University Hospital - Quirónsalud

www.oncohealth.eu/en / 2 Avenida Reyes Católicos, 28040, Madrid, Spain

31/12/2021 – 31/03/2022 – Sutton, United Kingdom

Visiting Physician in Medical Oncology

The Royal Marsden Hospital - Children and Young people and Lung cancer Unit

08/2018 – CURRENT

General Pathology Lecturer - Biomedicine Grade

University Francisco de Vitoria

www.ufv.es/welcome-to-ufv-madrid/ / Ctra. Pozuelo-Majadahonda, 28223, Pozuelo de Alarcón, Spain

12/2009 – 08/2010

Visiting Research Scientist

Dana-Farber Cancer Institute

www.dana-farber.org / 450 Brookline Avenue, 02215, Boston, United States

04/2018 – CURRENT

Human Physiology and Physiopathology Lecturer

GoFIR, GoBIR Academy

www.academiagofir.com / 14 Félix Boix 4B, 28036, Madrid, Spain

08/2006 – 12/2010

Molecular & Cellular Biology PhD Candidate

Center for Applied Medical Research (CIMA) - University of Navarra

www.cima.unav.edu/en/inicio / 55 Avenida Pio XII, 31008, Pamplona, Spain

12/2009 - 04/2010

Visiting Research Scientist

Broad Institute of MIT and Harvard University

www.broadinstitute.org / 415 Main Street, 02142, Cambridge, United States

EDUCATION AND TRAINING

05/2017 - 07/2022 - Madrid, Spain

Medical Oncology Specialist Doctor

Ministry of Health - Government of Spain

08/2011 - 06/2016 - 12 Pedro Cerbuna, Zaragoza, Spain

Grade in Medicine and Surgery

Medicine Faculty - University of Zaragoza

www.unizar.es

08/2006 - 04/2014 - 1 Irunlarrea, Pamplona, Spain

PhD in Molecular & Cellular Biology

Science Faculty - University of Navarra

"Characterization of prognostic genome aberrations in early NSCLC patients using SNP arrays"

Sobresaliente Cum Laude | www.unav.edu/en/home

08/2001 - 09/2006 - 1 Irunlarrea, Pamplona, Spain

Grade in Health Biology

Science Faculty - University of Navarra

www.unav.edu/en/home

2011 - 2012 - Valencia, Spain

Postgrade in Clinical Genetics

University of Valencia

www.uv.es/uvweb/college/en/university-valencia-1285845048380.html

2019 - 2021

MSc in Thoracic Oncology

CEU Cardenal Herrera University

2020 - 2022

MSc in Gastrointestinal Oncology

CEU Cardenal Herrera University

10/2021 - 06/2022

MSc in Aesthetic Medicine and Antiageing

CEU Cardenal Herrera University

09/2019 - CURRENT

MSc in Clinical Oncology (SEOM)

University of Girona

02/2021 - CURRENT

University Expert in Target therapies in Breast Cancer

European University of Madrid

08/2021 – CURRENT

MSc in Health Management and Medical Direction

CEU Cardenal Herrera University

01/2022 – CURRENT

MSc in Diagnosis and Treatment of Lung Cancer (GECP)

UAM - GECP

02/2022 – CURRENT

University Expert in Clinical Nutrition

European University of Madrid

LANGUAGE SKILLS

MOTHER TONGUE(S): Spanish

OTHER LANGUAGE(S):

English

Listening
B2

Reading
C1

Spoken production
B2

Spoken interaction
B2

Writing
C1

French

Listening
A2

Reading
B1

Spoken production
A2

Spoken interaction
A2

Writing
A2

CLINICAL RESEARCH INVOLVEMENT

Subinvestigator: Estudio Fase III, aleatorizado, doble ciego y controlado con placebo de atezolizumab mas carboplatino y etoposido con o sin tiragolumab (anticuerpo anti-TIGIT) en pacientes con cáncer de pulmón microcitico en estadio avanzado

Código GO41767 EudraCT 2019-003301-97

Subinvestigator: Estudio Fase IIIb, Carboplatino o cisplatino mas etopósido con atezolizumab en pacientes con cáncer de pulmón microcitico avanzado

Código ML41599 EudraCT 2019-002748-10

PUBLICATIONS

Publications

Original papers

- **The Clinical significance of PIWIL3 and PIWIL4 expression in Pancreatic cancer.** 2020; J Clin Med.
- **KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study.** 1, 2020; Cells
- **Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.** Oct 1, 2015; BMC Genomics
- **LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas.** Sep 1, 2013; British Journal of Haematology

Book chapters

- Montuenga LM., garcia-Chacon C., Orta A., Agorreta J. Capitulo: **Técnicas de localización in situ de ácidos nucleicos (Técnicas Histología y biología molecular)**. ISBN: 978-84-458-1964-7 Elsevier 2009
- Orta A.: Capitulo: **Linfocitosis hemofagocítica (LHH) secundaria a tratamiento combinado de inmunoterapia: el equilibrio entre la inmunosupresión grave y la hiperestimulación inmune (Casos Clínicos de Oncología)**. ISBN: 978-84-18568-32-9

PROJECTS

05/2021 - CURRENT

● **Research Project: Drug encapsulation in cell lines isolated exosomes for pancreatic cancer treatment**

Principal Investigator: Dr. Javier Martínez Useros

12/2010 - 12/2013

● **Research Project: Molecular characterization of early stage lung cancer specimens for biomarkers development in early detection context**

Principal Investigator: Dr. Luis Montuenga Badia

11/2009 - 12/2012

● **Research Project: Identification of prognostic genomic markers in early staged lung cancer patients by SNP arrays**

CONFERENCES AND SEMINARS

03/2019 > - Universidad Francisco de Vitoria

● **Seminar: New frontiers in Cancer Treatment**

06/2011 > - 14th World Conference on Lung Cancer (IASLC)

● **Poster: Improvement in the detection of genomic aberrations with single nucleotide polymorphism arrays using microdissected samples**

05/2010 > - 15th Congress of EHA

● **Poster: Integration of global SNP-based mapping and expression arrays with microRNA patterns reveals deregulated miRNAs and their gene candidate targets in acute myeloid leukemia**

07/2008 > - XIII International Congress of Histochemistry and Cytochemistry

● **Oral Communication: Molecular Analysis of lung carcinogenesis with new technical tools**

06/2008 > - 1st International Lung Cancer Conference

● Oral Communication: Genome-wide analysis of lung cancer cell lines by 500k SNP arrays

HONOURS AND AWARDS

● 06/2021

MERCK Clinical Oncology Case Report Award – MERCK Foundation

● 10/2009

Grant for formative period in an International Research Center – Fundación Bancaja - Universidad de Navarra

● 05/2009

RTICC grant for international formative stays – Red Tematica de Investigación Cooperativa en Cáncer

LICENSES & CERTIFICATIONS

● 05/2021

Lung Cancer Diagnosis and Treatment Certification (Lung Cancer Spanish Group)

● 03/2020

Good Clinical Practice and Development of Clinical Trials (The Global Health Network)

RECOMMENDATIONS

● Prof. Jesús García Foncillas – Head of Oncology Department – jgfoncillas@quironsalud.es – (+34) 900815019

Prof. Jesús García Foncillas could support a recommendation as a clinical oncologist and translational researcher.

● Dr. Luis Montuenga Badía – Head of Cancer Biomarkers Discovery Laboratory – lmontuenga@unav.es – (+34) 94819 4700

Dr. Luis Montuenga Badía could support a recommendation as a translational researcher.

● Dr. Maite Iglesias Badiola – Dean of Experimental Science Faculty - Universidad Francisco de Vitoria – maite.iglesias@ufv.es – (+34) 913510303

Dr. Maite Iglesias Badiola could support a recommendation as a University Lecturer